The Effect of High Dose Isoflavone Supplementation on Serum Reverse T\textsubscript{3} in Euthyroid Men With Type 2 Diabetes and Post-menopausal Women

Thozhukat Sathyapalan\textsuperscript{1}, Josef Köhrle\textsuperscript{2}, Eddy Rijntjes\textsuperscript{2}, Alan S. Rigby\textsuperscript{1}, Soha R. Dargham\textsuperscript{3}, Eric S. Kilpatrick\textsuperscript{4} and Stephen L. Atkin\textsuperscript{*}

\textsuperscript{1} Academic Diabetes, Endocrinology and Metabolism, Hull York Medical School, University of Hull, Hull, United Kingdom,
\textsuperscript{2} Institut für Experimentelle Endokrinologie, Charité-Universitätsmedizin Berlin, Berlin Institute of Health, CVK, Humboldt-Universität zu Berlin, Berlin, Germany, \textsuperscript{3} Weill Cornell Medical College Qatar, Doha, Qatar, \textsuperscript{4} Department of Clinical Chemistry, Sidra Medical and Research Center, Doha, Qatar

**Background:** The health benefits of soy are widely reported but there are queries on the effect of soy isoflavones on thyroid function and the underlying mechanism of action.

**Materials and Methods:** We examined the effect of soy isoflavones on reverse tri-iodothyronine (or 3,3',5'-tri-iodothyronine; rT\textsubscript{3}) in two studies comprising 400 patients: 200 men (study 1; 3 months) and 200 post-menopausal women (study 2; 6 months) who were randomized to consume 15 g soy protein with 66 mg of isoflavones (SPI) daily, or 15 g soy protein alone without isoflavones (SP) daily.

**Results:** SPI supplementation increased rT\textsubscript{3} serum concentration in both men 0.41 (0.12) vs. 0.45 (0.14) nmol/L and women 0.33 (0.12) vs. 0.37 (0.09) nmol/L at 3 months compared to SP that was not seen at 6 months. Thyroid stimulating hormone (TSH) serum concentrations increased while free thyroxine (fT\textsubscript{4}) concentrations decreased with 3 months of SPI compared to SP supplementation for both men and women. rT\textsubscript{3} correlated with TSH in both studies (\(p = 0.03\)) but not with either fT\textsubscript{3} or fT\textsubscript{4}. fT\textsubscript{3} levels did not differ between the SPI and SP preparations.

**Conclusion:** Soy isoflavones transiently increased rT\textsubscript{3} levels within 3 months though reverted to baseline at 6 months. The mechanism for this would be either rT\textsubscript{3} degrading deiodinase 1 and/or deiodinase 2 activities are transiently inhibited at 3 months, or inhibition of deiodinase 3, which generates rT\textsubscript{3} from T\textsubscript{4} is induced at 6 months. These changes were mirrored in the TSH concentrations, suggesting that short-term high dose isoflavone transiently impairs thyroid function in the first 3 months and may impact on general health during this period.

**ISRCTN Registry:** ISRCTN 90604927; ISRCTN34051237.

**Keywords:** soy, isoflavones, phytoestrogens, reverse tri-iodothyronine, tri-iodothyronine, thyroxine, TSH
INTRODUCTION

The consumption of soy food products have increased due to the reported potential health benefits that have been suggested to be due to the isoflavone components, leading to the development of isoflavone supplements and the fortification of foods with isoflavones (1, 2). It has been suggested that the soy isoflavones might provide protection against breast and prostate cancer (3–5), osteoporosis (6), cardiovascular diseases (7, 8) and alleviate hot flashes (9). However, there are concerns in susceptible individuals that soy may adversely affect thyroid function (10–14). The mechanism by which soy isoflavones may interfere with thyroid function is unclear, but it is critical to understand given the wide spread use of soy products. Animal studies have suggested that soy isoflavones interfere with thyroid function via thyroid peroxidase inhibition, as well as, with tissue deiodinase enzyme activities, which may affect extrathyroidal thyroid hormone metabolism, including rT₃ concentrations (15). Isoflavones might also displace thyroid hormones from their distributor proteins in the blood (16).

We have shown that high dose isoflavone intake, in comparison with isoflavone free soy, impair thyroid function in patients with type 2 diabetes (T2DM) (Study 1) (17) and also in post-menopausal healthy women (Study 2) (18). Study 1 was a randomized double-blind parallel study investigating the effect of soy isoflavones on testosterone serum concentrations in men with T2DM; 3 months of high dose isoflavone intake resulted in a significant increase in serum concentrations of thyrotropin (TSH) and a reduction of free thyroxine (fT₄) with no changes in serum free tri-iodothyronine (fT₃) concentration. Similarly, in study 2, a double-blind randomized parallel study investigating the effect of high dose isoflavone intake on bone turnover markers in women within 2 years of onset of menopause, 6 months of high dose isoflavone intake resulted in a significant increase in TSH and reduction of fT₄ with no changes in fT₃. As rT₃ is a major endogenous T₄ metabolite, probably devoid of major biological action in adults, we analyzed potential rT₃ concentration changes in serum, which might be harbingers of altered thyroid hormone distribution and metabolism (19). We conducted this post-hoc analysis to understand the impact of high dose isoflavones on rT₃ concentrations and their correlation with other thyroid measurement parameters tests including fT₃, fT₄ and TSH.

RESEARCH DESIGN AND METHODS

Study 1 involved 200 men aged between 45 and 75 years with T2DM, low early morning total testosterone concentrations (total testosterone less than the lower level of the reference range of 12 nmol/L) and normal gonadotropins who participated in a randomized double blind parallel study investigating the effect of soy isoflavones on serum testosterone concentrations (17). They were randomized either to intake of 15 g soy protein with 66 mg of isoflavones (SPI) per day or 15 g soy protein alone without any isoflavones (SP) per day for 3 months in the form of snack bars (Figure 1A). Study 2 involved 200 healthy women within 2 years of the onset of their menopause who were recruited (20) to assess the impact of high dose soy isoflavones on bone turnover markers. They were randomized into either the SPI group (15 g soy protein with 66 mg of isoflavones) or SP group (15 g soy protein alone, isoflavone free) daily intake for a period of 6 months in the form of snack bars (Figure 1B). Thyroid function tests including fT₃, fT₄, and TSH were secondary outcomes for both studies.

Participants were required to avoid food products containing soy, alcohol, mineral, or vitamin supplementation. All patients were euthyroid and none of the patients were on thyroxine supplementation or on medications, which are known to affect thyroid function. The snack bars were consumed twice daily between meals. Dietary reinforcement together with measurement of plasma isoflavone concentrations was undertaken at each visit to ensure adherence. All subjects gave their written informed consent. Both studies received ethical approval by the Research Ethics Committee (East Yorkshire & North Lincolnshire Research Ethics Committee, ref: 09/H1304/45 and 09/1304/45). Computer-generated block randomization list was performed by Essential Nutrition Ltd., Brough, UK, who held the randomization codes for both the studies.

TSH, fT₃, and fT₄ assays were performed on an Abbott Architect i4000 immunoassay analyser (Abbott Diagnostics Division, UK) as batched samples. Analytical performance in terms of imprecision at discreet levels (% CV, Mean) for fT₄ was 4%, 13.7 pmol/L, for fT₃ was 11.2%, 0.33 nmol/L, and that of TSH was 4.2%, 1.32 mU/L. The rT₃ concentrations were measured in duplicate by competitive radioimmunoassay (total rT₃ RIA, lot R-EW-125-1614A; Radim Deutschland GmbH, Freiburg, Germany) according to the manufacturer's instructions as a batched analysis. The assay range was 0.04–3.10 nmol/L and inter-assay %CV was <11.2%. The isoflavones were extracted and analyzed from serum by LGC, Fordham, Cambridgeshire, UK using isotope-dilution LC-MS/MS (21). LC-MS/MS was conducted using a Sciex4000 Qtrap with separation achieved using a C18 column and mobile phases of acetonitrile and water, both containing acetic acid (17).

Study Product

“The intervention consisted of a snack bar containing 7.5 g isolated soy protein powder (Solcon F, Solbar Industries, Israel) with 33 mg of isoflavones (SPI) (Solgen 40, Solbar Industries, Israel) given twice daily between meals (15 g soy protein and 66 mg of isoflavones per day), or 7.5 g of the isolated soy protein given twice daily (15 g soy protein per day without isoflavones per day) as control (SP). The latter had an isoflavone concentration of <300 parts per billion following serial alcohol extraction by Dishman Ltd., India (20); and product isoflavones assayed by FERA, Sand Hutton, UK (20). Analysis showed the composition of the dose materials to be 12% glycine, 35% daidzein, and 54% genistin as aglycones. 90% of isoflavones were in the primary glucoside form, with the remaining 10% as aglycones as malonyl and acetyl glucosides. The snack bars were consumed twice daily between meals for 6 months. The study bars were prepared and packaged by Halo foods, Swindon, UK.” Soy bars were identical and
FIGURE 1 | Flow diagrams detailing the participants through studies 1 and 2 from recruitment to the end of the studies. (A) Flow diagram of participants through the study 1. (B) Flow diagram of participants through the study 2.

had similar macronutrient content and a tasting panel had determined that there was no discernible difference between the 2 products.

**Statistical Analysis**

This is a post-hoc exploratory analysis of two studies to understand the impact of high dose isoflavones on rT3 concentrations and their correlation with other serum thyroid hormone measurement parameters tests including fT3, fT4, and TSH hence apriori power calculation was not done for changes in rT3.

Baseline continuously distributed data is presented as median (25/75th centiles); categorical data by n (%). Within-group differences (difference between 12 weeks/24 weeks values and baseline values) are shown for each treatment group separately by a mean and a standard deviation (SD). Between-group comparisons were performed using the independent sample t-test. The t-test assumes equal variance between groups. Changes of rT3 concentrations (ΔrT3) with each supplementation was correlated with changes in fT3 (ΔfT3), changes in fT4 (ΔfT4) and changes in TSH (ΔTSH) by Spearman correlation coefficient method. For all statistical analyses, a two-tailed $P < 0.05$ was considered to indicate statistical significance. Statistical analysis was performed using the STATA statistical computer package (StataCorp 2013. *Stata Statistical Software*: StataCorp LP, USA).

**RESULTS**

In Study 1, there was a significant increase in rT3 with SPI supplementation [0.41 (0.12) vs. 0.45 (0.14) nmol/L] at 3 months compared to SP supplementation [0.43 (0.10) vs. 0.40 (0.15) $p$-value $< 0.001$] (Tables 1, 2) in men with type 2 diabetes. SPI supplementation increased TSH within 3 months [Mean (SD)] [1.81 (0.92) vs. 3.23 (1.03) mU/L] compared to SP supplementation [1.82 (0.93) vs. 1.96 (1.11) mU/L]. Conversely, SPI supplementation decreased free T4 within 3 months [12.68 (1.90) vs. 11.09 (2.00) pmol/L] compared to SP supplementation [13.06 (1.74) vs. 12.74 (1.62) pmol/L]. There were no changes in fT3 with 3 months of either SPI or SP supplementation. There was a significant correlation between changes in rT3 with TSH ($r = 0.52; p = 0.03$) but no correlation with changes in fT3 ($r = 18; p = 0.81$) and fT4 ($r = 13; p = 0.62 0.81$).

In Study 2 in healthy women within 2 years of menopause (Table 3), SPI supplementation increased rT3 [0.33 (0.12) vs. 0.37 (0.09) nmol/L] compared to SP supplementation ($p < 0.001$) within 3 months. The rT3 decreased after 6 months 0.31 (0.13)
TABLE 1 | Changes in reverse T3 at 3 months for study 1 and at 3 and 6 months for study 2.

|                  | Baseline | 3 months | p-value (baseline vs. 3 months between groups) | 6 months | p-value (baseline vs. 6 months between groups) | p-value (3 vs. 6 months between groups) |
|------------------|----------|----------|-----------------------------------------------|----------|-----------------------------------------------|-----------------------------------------|
| SPI              | 0.41 (0.12) | 0.45 (0.14) | <0.001                                        |          |                                               |                                         |
| SP               | 0.43 (0.10) | 0.40 (0.15) |                                               |          |                                               |                                         |

**STUDY 1**

**STUDY 2**

|                  | Baseline | 3 months | p-value (baseline vs. 3 months between groups) | 6 months | p-value (baseline vs. 6 months between groups) | p-value (3 vs. 6 months between groups) |
|------------------|----------|----------|-----------------------------------------------|----------|-----------------------------------------------|-----------------------------------------|
| SPI              | 0.33 (0.12) | 0.37 (0.09) | <0.001                                        | 0.31 (0.13) | 0.81                                           | 0.001                                   |
| SP               | 0.33 (0.11) | 0.33 (0.12) |                                               | 0.30 (0.12) |                                               |                                         |

SPI, 15 g soy protein with 66mg of isoflavones; SP, 15 g soy protein alone isoflavone free. Results in Mean (SD).

TABLE 2 | Baseline characteristics of study 1 participants.

| Parameters                  | Soy protein without isoflavone | Soy protein with isoflavone |
|-----------------------------|--------------------------------|------------------------------|
| Body mass index (kg/m²)     | 31.6 (29.2, 35.0)               | 31.8 (28.8, 34.7)            |
| Age (years)                 | 52.0 (50.0, 55.0)               | 52.0 (50.0, 55.0)            |
| HbA1c (mmol/mol)            | 58 (53, 64)                     | 56 (52, 60)                  |
| Duration of diabetes (years)| 7.9 (4.4, 9.1)                  | 7.3 (4.2, 8.8)               |
| fT4 (pmol/L)                | 13.0 (12.0, 14.0)               | 12.0 (12.0, 14.0)            |
| fT3 (pmol/L)                | 4.6 (4.2, 4.9)                  | 4.6 (4.2, 5.0)               |
| TSH (mU/L)                  | 1.6 (1.2, 2.5)                  | 1.6 (1.2, 2.4)               |

Data are provided as medians (25/75th centiles). fT4, free thyroxine; fT3, free tri-iodo thyronine; TSH, thyroid stimulating hormone.

TABLE 3 | Baseline characteristics of study 2 participants.

| Parameters                  | Soy protein without isoflavone | Soy protein with isoflavone |
|-----------------------------|--------------------------------|------------------------------|
| Body mass index (kg/m²)     | 24.6 (22.7, 28.4)               | 26.3 (24.3, 30.7)            |
| Age (years)                 | 52 (50, 55)                     | 52 (49, 56)                  |
| fT4 (pmol/L)                | 13 (12, 14)                     | 13 (13, 15)                  |
| fT3 (pmol/L)                | 4.7 (4.3, 4.9)                  | 4.6 (4.3, 5.1)               |
| TSH (mU/L)                  | 1.6 (0.9, 2.3)                  | 1.5 (0.9, 2.2)               |

Data are provided as medians (25/75th centiles). fT4, free thyroxine; fT3, free tri-iodo thyronine; TSH, thyroid stimulating hormone.

DISCUSSION

There was a significant increase in rT3 in both studies after 3 months of high dose isoflavone supplementation, whereas the rT3 values did not differ in isoflavone-free soy, suggesting that it is the isoflavone component that is responsible for the rT3 changes seen. However, in the study 2 involving post-menopausal women the rT3 decreased to baseline values after 6 months of SPI supplementation, suggesting that the isoflavone induced changes are transient and return to normal pretreatment thyroid homeostasis over a 6-months period.

In both studies, there was a reduction in fT4 and a corresponding rise in TSH, suggesting that the feedback response of the hypothalamo-pituitary-thyroid axis was intact. In situations where the thyroid cannot maintain thyroid hormone production, either due to an autoimmune process and/or lack of the essential trace element iodine, there would be a shift in thyroidal production from a 20:1 T4:T3 ratio to a ratio more in favor of T3. A preferential production and secretion of T3 compared to T4 could potentially explain why there were no significant changes in fT3 despite changes in TSH and fT4.

There were no changes in fT3 at 3 months between 3 and 6 months. There were no differences in the fT3 between both preparations.
effects solely restricted to T2DM patients or post-menopausal women.

Serum T4 is metabolized either to the active thyroid hormone T3 or to the inactive rT3 in a reciprocal manner depending upon the relative actions of the tissue deiodinase enzymes types 1 to 3. The mechanism of the increase in rT3 seen in both studies is unclear. One of the main sources of rT3 is the peripheral conversion of thyroxine to rT3. The enzyme responsible for this is deiodinase type 3 and it could be hypothesized that isoflavones may activate deiodinase type 3 (25), but no data has been reported on direct stimulation of expression of any of the deiodinases by isoflavones. Degradation of rT3 is mainly accomplished by hepatic and renal deiodinase type 1, but also by deiodinase type 2 (25). Therefore, another plausible explanation would be that isoflavones (transiently) inhibit hepatic deiodinase 1 (and/or extrahepatic deiodinase 2) (25), which would lead to accumulation of rT3 in blood. However, in rat-studies we have shown that deiodinase type 1 activity in the liver is increased after 16 weeks of isoflavone treatment (15), which might be due to higher hepatic uptake and exposure to thyroid hormone which may be displaced by flavonoids from its binding to transthyretin (16, 26). Administration of high concentrations of rT3, administered in rodent experiments, did not affect serum TSH and thyroid hormones, albeit type 2 deiodinase activity was inhibited and hepatic gene expression was affected (27). The short half-life and rapid turnover of rT3 might result in these transient changes and flavonoid effects on deiodinase isoenzymes and transthyretin might mainly manifest as variations in rT3 serum concentrations which is only weakly bound to serum distribution proteins compared to T4 and T3. Whether the thyroid itself is also affected by isoflavones and/or responds to altered TSH concentration, which might induce activity and expression of type 1 and type 2 deiodinases and thus maintain T3 concentration, requires detailed kinetic studies (28). There may be multiple mechanisms through which isoflavones act on thyroid hormone metabolism, distribution, and/or transport systems with a complexity that needs further elucidation. It is also unknown if the isoflavone effects would be different between patients with and without autoimmune thyroid disease.

Reduced circulating levels of rT3 are a sensitive marker of ill health especially in context of elevated rT3 (29). In a population of elderly men, who were independently living, serum rT3 concentrations increased with age and the presence of comorbidity (29). Higher serum rT3 concentrations may result from decreased peripheral metabolism of TH due to the aging process itself and/or disease and may reflect a catabolic state (29). Indeed, fasting, cold exposure, and even minor infective or inflammatory disease are sufficient to reduce serum rT3 and elevate rT3 concentrations in otherwise-healthy individuals (30, 31).

In a cohort of elderly people, baseline serum rT3 concentration was associated with all-cause mortality during a 9-years period of follow up, suggesting that rT3 may be a more sensitive marker for non-thyroidal illness than fT3 (32). No significant mortality associations were found with serum fT3, fT4 or TSH concentrations. However, in men lower serum TSH, and in women higher rT3 concentrations, predicted disability (32). These findings broadly confirm those of previous studies of older people (33, 34), and are in line with the known pathophysiological mechanisms whereby low fT3 and higher rT3 concentrations are non-specifically associated with increasing ill health and disease burden (31). In the elderly, high rT3 is a stronger predictor of all-cause mortality than low fT3 independent of disease burden (32).

Dietary intake of isoflavones in Asian soy diets has been estimated to be in the range of 30–50 mg per day of combined isoflavone aglycone equivalents (35, 36). In Western countries an average daily intake of ~2 mg isoflavones is seen though estimated to be 16 mg in vegetarians (37); therefore, the dose of 66 mg of isoflavones used in this study may be considered to be in the pharmacological range for this study purpose.

In conclusion, these studies show that the isoflavone component of soy protein transiently increases rT3 concentrations when supplemented over a period of 3 months but afterwards rT3 concentrations reverted to baseline at 6 months, perhaps due to deiodinase 3 inhibition. These changes were mirrored in the TSH values, suggesting that high dose isoflavones may transiently impair thyroid homeostasis, though it is not clear if this would impact clinically on general health.

**AUTHOR CONTRIBUTIONS**

TS, EK, and SA devised the study. JK and ER measured the rT3 whilst. AR and SD performed the statistical analysis. All authors contributed to the writing and final review of the manuscript.

**FUNDING**

This study was supported by the Food Standards Agency, United Kingdom (T01057 and T01060). The sponsors did not influence the study design; the collection, analysis, and interpretation of data; writing of the report; and decision to submit the paper for publication. Any views or opinions expressed do not necessarily represent those of the FSA and are solely those of the authors. The publication of this article was funded by the Qatar National Library.

**REFERENCES**

1. Nurmi T, Mazur W, Heinonen S, Kokkonen J, Adlercreutz H. Isoflavone content of the soy based supplements. J Pharm Biomed Anal. (2002) 28:1–11. doi: 10.1016/S0731-7085(01)00612-4
2. Setchell KD. Soy isoflavones—Benefits and risks from nature’s selective estrogen receptor modulators (SERMs). J Am Coll Nutr. (2001) 20 (Suppl. 5):354S–62S. discussion: 81S–83S. doi: 10.1080/07315724.2001.10719168
3. Yamamoto S, Sobue T, Kobayashi M, Sasaki S, Tsugane S. Soy, isoflavones, and breast cancer risk in Japan. J Nat Cancer Inst. (2003) 95:906–13. doi: 10.1093/jnci/95.12.906
4. Messina MJ. Emerging evidence on the role of soy in reducing prostate cancer risk. Nutr Rev. (2003) 61:117–31. doi: 10.1301/nr.2003.apr.117-131
5. Lamartiniere CA, Cotroneo MS, Fritz WA, Wang J, Mentor-Marcel R, Elgavish A. Genistein chemoprevention: timing and mechanisms of
action in murine mammary and prostate. J Nutr. (2002) 132:5525–85. doi: 10.1093/jn/132.5.552S
6. Messina M, Ho S, Alekel DL. Skeletal benefits of soy isoflavones: a review of the clinical trial and epidemiologic data. Curr Opin Clin Nutr Metab Care (2006) 7:649–58. doi: 10.1097/0000175197-200411000-00010W
7. Weggemans RM, Trautwein EA. Relation between soy-associated isoflavones and LDL and HDL cholesterol concentrations in humans: a meta-analysis. Eur J Clin Nutr. (2003) 57:940–6. doi: 10.1038/sj.ejn.1601628N
8. Nestel P. Isoflavones: their effects on cardiovascular risk and functions. Curr Opin Lipidol. (2003) 14:3–8. doi: 10.1097/00001072-200302000-00002M
9. Messina M, Hughes C. Efficacy of soyfoods and soybean isoflavone supplements for alleviating menopausal symptoms is positively related to initial hot flush frequency. J Med Food (2003) 6:1–11. doi: 10.1089/109662003765184697P
10. Fitzpatrick M. Soy formulas and the effects of isoflavones on the thyroid. N Z Med J. (2000) 113:24–6.F
11. Doerge DR, Sheehan DM. Goitrogenic and estrogenic activity of soy isoflavones. Environ Health Perspect. (2002) 110 (Suppl. 3) :349–53. doi: 10.1289/ehp.2002110349B
12. Sathyapalan T, Manuchehri AM, Thatcher NJ, Rigby AS, Chapman T, et al. The effect of soy phytoestrogen supplementation on thyroid status and cardiovascular risk markers in patients with subclinical hypothyroidism: a randomized, double-blind, crossover study. J Clin Endocrinol Metab. (2011) 96:1442–9. doi: 10.1210/jc.2010-2255B
13. Messina M, Redmond G. Effects of soy protein and soybean isoflavones on thyroid function in healthy adults and hypothyroid patients: a review of the relevant literature. Thyroid (2006) 16:249–58. doi: 10.1089/thy.2006.16.249H
14. Huser S, Guth S, Joost HG, Soukup ST, Kohrle J, Kreienbrock L, et al. Effects of isoflavones on breast tissue and the thyroid hormone system in humans: a comprehensive safety evaluation. Arch Toxicol. (2018) 92:2703–48. doi: 10.1007/s00204-018-2279-8S
15. Sosic-Jurjevic B, Filipovic B, Jankovic J, et al. Effects of age and soybean isoflavones on hepatic cholesterol metabolism and thyroid hormone availability in acyclic female rats. Exp Gerontol. (2017) 92:74–81. doi: 10.1016/j.exger.2017.03.016F
16. Cettour-Rose P, Visser TJ, Burger AG, Rohner-Jeanrenaud F. Inhibition of pituitary type 2 deiodinase by reverse triiodothyronine does not alter thyroxine-induced inhibition of thyrotropin secretion in hypothyroid rats. Eur J Endocrinol. (2005) 153:429–34. doi: 10.1530/ej.1.01984B
17. Sathyapalan T, Rigby AS, Bhasin S, Thatcher NJ, Kilpatrick ES, et al. Soy reduces bone turnover markers in women during early menopause: a randomized controlled trial. J Bone Miner Res. (2006) 5:6883–8. doi: 10.1210/1jemc.56-5-883J
18. van den Beld AW, Visser TJ, Feelders RA, Grobbée DE, Lamberts SW. Thyroid hormone concentrations, disease, physical function, and mortality in elderly men. J Clin Endocrinol Metab. (2005) 90:6403–9. doi: 10.1210/jc.2005-0872M
19. Spencer CA, Lum SM, Wilber JF, Kaptein EM, Nicoloff JT. Dynamics of serum thyrotropin and thyroid hormone changes in fasting. J Clin Endocrinol Metab. (1983) 56:883–8. doi: 10.1210/jcem.56-5-883A
20. de Vries EM, Fliers E, Boelen A. The molecular basis of the non-thyroidal illness syndrome. J Endocrinol. (2015) 225:R67–81. doi: 10.1530/JOE-15-01333A
21. Pearce SH, Razvi S, Yadegarfar ME, Martin-Ruiz C, Kingston A, Collerton J, et al. Serum thyroid function, mortality and disability in advanced old age: the newcastle 85+ study. J Clin Endocrinol Metab. (2016) 101:4835–94. doi: 10.1210/jc.2016-1935F
22. Guuskeloo J, van Exel E, de Craen AJ, Meinders AE, Frolich M, Westendorp RG. Thyroid status, disability and cognitive function, and survival in old age. JAMA (2004) 292:2591–9. doi: 10.1001/jama.292.21.2591G
23. Waring AC, Arnold AM, Newman AB, Buzkova P, Hirsch C, Cappola AR. Longitudinal changes in thyroid function in the oldest old and survival: the cardiovascular health study all-stars study. J Clin Endocrinol Metab. (2012) 97:3944–50. doi: 10.1210/jc.2012-2481R
24. Wakai K, Egami I, Kato K, Kawamura T, Tamakoshi A, Lin Y, et al. Dietary intake and sources of isoflavones among Japanese. Nutr Cancer (1999) 33:139–45. doi: 10.1207/s15327914nc330204S
25. Messina M. Isoflavone intakes by Japanese were overestimated. Am J Clin Nutr. (1995) 62:645. doi: 10.1093/ajcn/62.3.645O
26. de Kleijn MJ, van der Schouw YT, Wilson PW, Adarceuz H, Mazur W, Grobbée DE, et al. Intake of dietary phytoestrogens is low in postmenopausal women in the United States: the Framingham study(1–4). J Nutr. (2001) 131:1826–32. doi: 10.1093/jn/131.6.1826N

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2018 Sathyapalan, Köhrle, Rijntjes, Rigby, Dargham, Kilpatrick and Aitkin. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.